Journal article

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors

Abstract:: Urinary albumin-to-creatinine ratio (uACR) measured on spot samples provides a convenient method to screen for, diagnose, stage, and monitor chronic kidney disease (CKD),1Stevens P.E. Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158: 825-830Crossref PubMed Scopus (1963) Google Scholar and change in albuminuria is proposed as a surrogate outcome for CKD progression...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Chapman, D., Judge, P. K., Sardell, R. J., Staplin, N., Arnold, T., Zhu, D., Ng, S., Moffat, S., Landray, M. J., Baigent, C., Hill, M., Haynes, R., Clark, S., & Herrington, W. G. (2023). Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors. Kidney International, 103(4), 787–790.

MLA Style

Chapman, D, et al. “Interference of Urinary Albumin-to-Creatinine Ratio Measurement by Glycosuria: Clinical Implications When Using SGLT-2 Inhibitors.” Kidney International, vol. 103, no. 4, 2023, pp. 787–90.

Chicago Style

Chapman, D, PK Judge, RJ Sardell, et al. 2023. “Interference of Urinary Albumin-to-Creatinine Ratio Measurement by Glycosuria: Clinical Implications When Using SGLT-2 Inhibitors.” Kidney International 103 (4): 787–90.
Print

Access Document

Files:: Chapman_et_al_2023_Interference_of_urinary.pdf

(Preview, Version of record, pdf, 801.6KB, Terms of use)

Publisher copy:: 10.1016/j.kint.2022.12.027

Authors

+ Chapman, D More by this author

Role:: Author

+ Judge, PK More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author

+ Sardell, RJ More by this author

Role:: Author
ORCID:: 0009-0007-1640-8018

+ Staplin, N More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author
ORCID:: 0000-0003-4482-4418

+ Arnold, T More by this author

Role:: Author

More authors...

+ Medical Research Council More from this funder

Funder identifier:: https://ror.org/03x94j517
Grant:: MR/R007764/1; MC_U137686860; MC_U137686860

Publisher:: Elsevier
Journal:: Kidney International More from this journal
Volume:: 103
Issue:: 4
Pages:: 787-790
Place of publication:: United States
Publication date:: 2023-02-02
Acceptance date:: 2022-12-27
DOI:: 10.1016/j.kint.2022.12.027
EISSN:: 1523-1755
ISSN:: 0085-2538
Pmid:: 36736537

Language:: English
Keywords:: sodium-glucose transporter 2 inhibitors

glycosuria

diabetes mellitus

type 2

creatinine

hypoglycemic agents

albumins
Pubs id:: 1326837
Local pid:: pubs:1326837
Source identifiers:: W4319034726
Deposit date:: 2024-10-11
ARK identifier:: ark:/29072/ora_d0ac268779e94f52a1fc4c92a7a16c6a

Terms of use

Copyright holder:: International Society of Nephrology
Copyright date:: 2023
Rights statement:: © 2023, International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Licence:: CC Attribution (CC BY)

Views and Downloads

Views and downloads will return soon

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP